ORAGENICS, INC. Increase (Decrease) in Accrued Interest Receivable, Net
ORAGENICS, INC. (OGEN) reported Increase (Decrease) in Accrued Interest Receivable, Net of -$53.08 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-08.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet · last filed 2026-05-08
- ORAGENICS, INC. increase (decrease) in accrued interest receivable, net for the quarter ending 2026-03-31 was -$53.08K.
| Period end | Increase (Decrease) in Accrued Interest Receivable, Net 3 month |
|---|---|
| 2026-03-31 | -$53.08K 10-Q · filed 2026-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |